Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids (terminated appraisal). NICE technology appraisal guidance 839
National Institute for Health and Care Excellence (NICE)
Record ID 32018011880
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta839
Year Published:
2022
URL for published report:
https://www.nice.org.uk/guidance/ta839
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Graft vs Host Disease
- Nitriles
- Pyrazoles
- Pyrimidines
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.